Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2G | O75747 | 4/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.47 |
| ▸ | PI4KA | P42356 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393257 | 0.87 | MEN1 (0.43) | PIK3C2GPI4KBPI4KAMEN1KMT2A | |
| SCHEMBL2396147 | 0.84 | MEN1 (0.56) | MEN1KMT2APIK3CGPIK3CDPIK3CA | |
| SCHEMBL2395311 | 0.83 | PIK3C2G (0.42) | PIK3C2GPI4KBPI4KAMEN1KMT2A | |
| SCHEMBL6276205 | 0.75 | MEN1 (0.41) | PIK3C2GPI4KBPI4KAMEN1KMT2A | |
| SCHEMBL49105 | 0.74 | PIK3CG (0.69) | PIK3C2GPI4KBPI4KAPIK3CGPIK3CD | |
| SCHEMBL2396736 | 0.72 | PIK3CD (0.56) | MEN1KMT2APIK3CGPIK3CDPIK3CA | |
| SCHEMBL2395156 | 0.72 | CDK2 (0.59) | MEN1KMT2APIK3CGPIK3CDPIK3CA | |
| SCHEMBL2398099 | 0.70 | MEN1 (0.45) | MEN1KMT2APIK3CGPIK3CDPIK3CA | |
| SCHEMBL6276191 | 0.68 | CDK2 (0.41) | MEN1KMT2APIK3CGPIK3CDPIK3CA | |
| SCHEMBL2394578 | 0.67 | MEN1 (0.55) | MEN1KMT2APIK3CGPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | PIK3C2G 392/4885PI4KB 56/4885PI4KA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.